Rising Antifungal Resistance in Candidozyma auris : Signals, Gaps, and the Path Forward
Clinical Infectious Diseases · 23.07.2026 · 83 (1) · 100-102
DOI: 10.1093/cid/ciag258 ↗Kurz gefasst
Kommentar in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.05.2026. Verfasst von Rosanne Sprute und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicin…. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
The continued global expansion of Candidozyma auris as a multidrug-resistant fungal pathogen has fundamentally altered the clinical and epidemiological landscape of invasive fungal infections. Its propensity for nosocomial transmission, persistence in healthcare environments, and multidrug resistance has elevated it from an emerging curiosity to a sustained public health threat. In this context, the study by Das et al provides an important and timely contribution to the field by capturing more than a decade of antifungal susceptibility patterns and resistance mechanisms in a large national collection of clinical C. auris isolates from India. The scale, duration, and integration of phenotypic and molecular analyses distinguish this work from the accumulating descriptive literature and make it highly relevant for clinicians, microbiologists, and public health stakeholders. The most striking and clinically relevant message emerging from this study is the documented increase in resistance to amphotericin B and echinocandins over time. While high fluconazole resistance in C. auris is well established, the apparent rise in resistance to other antifungal agents is deeply concerning. As therapeutic options for invasive candidiasis are already limited, reduced antifungal activity in these classes further narrows the already fragile treatment landscape [1].
Autor:innen und Institutionen
- Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, Cologne, Germany.
- Division of Infectious Diseases, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
- Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
ORCID-Profile: Rosanne Sprute, Oliver A Cornely
Zitieren
APA
Sprute, R., & Cornely, O. A. (2026). Rising Antifungal Resistance in Candidozyma auris : Signals, Gaps, and the Path Forward. Clinical Infectious Diseases, 83(1), 100-102. https://doi.org/10.1093/cid/ciag258
Vancouver
Sprute R, Cornely OA. Rising Antifungal Resistance in Candidozyma auris : Signals, Gaps, and the Path Forward. Clinical Infectious Diseases. 2026;83(1):100-102. doi:10.1093/cid/ciag258
BibTeX
@article{Sprute2026,
author = {Sprute, Rosanne and Cornely, Oliver A},
title = {Rising Antifungal Resistance in Candidozyma auris : Signals, Gaps, and the Path Forward},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {83},
number = {1},
pages = {100--102},
doi = {10.1093/cid/ciag258}
}
EUVIMED